Effect of Switching From Cigarette Smoking to IQOS on Exercise Capacity

Philip Morris

Status

Completed

Conditions

Exercise Capacity

Smoking

Treatments

Other: IQOS without Exercise Training Program

Other: Cigarette Smoking + Exercise Training Program

Other: Smoking Abstinence + Exercise Training Program

Other: IQOS + Exercise Training Program

Study type

Interventional

Funder types

Industry

Identifiers

NCT03887117

P1-EXC-01-EU

Details and patient eligibility

About

This exploratory study is part of the global clinical assessment program of IQOS. It was designed to provide scientific evidence to further substantiate the reduced risk potential of using a heated tobacco product (the Tobacco Heating System [THS] marketed as IQOS) as compared to smoking cigarettes. The main goals of this exploratory study were to assess whether switching from cigarette smoking to using IQOS would influence 1) maximum oxygen uptake during incremental exercise (VO2max) and exercise capacity, 2) ability to perform exercise training and thereby influence 3) VO2max after 12 weeks of exercise training, 4) physiological parameters and biological health markers, and finally 5) physical activity levels in daily life.

Full description

This exploratory study, with healthy adult smokers, was designed without product use restrictions (ad libitum product use) in order to replicate as closely as possible "real life" conditions. Subjects randomized to the cigarette and IQOS arms were asked to buy their own cigarettes or HeatSticks, respectively. Subjects randomized to the smoking abstinence (SA) arm were instructed to stay smoking abstinent until the end of the study. Subjects in the SA arm received smoking abstinence support and, in order to prevent relapse to cigarette smoking during the training program, were also allowed to use nicotine replacement therapy.

Mobile health technology was used in the study to explore the impact on switching from smoking to using IQOS on physical activity in daily real-world living conditions. The wearable enabled non-invasive recording of physical activity in an objective manner throughout the study. However, results collected from this device will be reported separately.

It should be noted that some study outcomes were reported graphically, rather than numerically. Consequently, these outcomes have not been included in this results disclosure.

Enrollment

94 patients

Sex

All

Ages

21 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Smoking, healthy subject based on safety laboratory, ECG, spirometry, vital signs, physical examination, medical history and Investigator's assessment.
Subject has been smoking for at least three years prior to V1.
Subject has been smoking ≥ 10 cigarettes per day over the last 12 months. Smoking status will be verified by a urinary cotinine ≥ 200 ng/mL and CO exhaled breath test > 10 ppm both at V1 and V2.
Subject does not plan to quit smoking within 6 months after V1.

Exclusion criteria

Subject has a clinically relevant disease which requires medication (including but not limited to gastrointestinal, renal, hepatic, neurological, hematological, endocrine, oncological, urological, immunological, pulmonary [such as but not limited to pulmonary oedema, asthma], and cardiovascular [such as, but not limited to myocardial infarction, unstable angina, uncontrolled arrhythmias, heart failure], disease) or any other clinically significant medical condition (including abnormal safety laboratory result as per CTCAE), which as per the judgment of the Investigator would jeopardize the safety of the subject.
Subject performs more than 45 min of vigorous physical activity per week.
Subject takes medication influencing blood volume such as erythropoietin, diuretics and beta blockers, or diabetic medications.
Subject cannot participate in the study for any reason other than medical as per the Investigator's judgment (e.g. psychological and/or social reason)
For women only: subject is pregnant (does not have negative pregnancy tests at V1 and at V2) or is breastfeeding.
For women of childbearing potential : female subject who does not agree to using an acceptable method of effective contraception during the entire study.
Subject has a BMI < 18.5 kg/m2 or BMI ≥ 30 kg/m2.
Subject has a positive urine drug screen.
Subject has been previously screened for this study.
Subject, or one of their family members (e.g., spouse, parent, sibling or child), is a current or former employee of the tobacco industry.
Subject, or one of their family members (e.g. spouse, parent, sibling or child), is an employee of the investigational site or any other parties involved in the study.
Subject is legally incompetent, or physically or mentally incapable of giving consent (e.g., emergency situation, under guardianship, prisoners, or subjects who are involuntarily incarcerated).

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

94 participants in 4 patient groups

IQOS-1

Active Comparator group

Description:

IQOS + Exercise Training Program Subjects randomized to IQOS use will switch to IQOS use and participate in an exercise training program.

Treatment:

Other: IQOS + Exercise Training Program

IQOS-2

Active Comparator group

Description:

IQOS without Exercise Training Program Subjects randomized to IQOS use will switch to IQOS use, but will not participate in an exercise training program.

Treatment:

Other: IQOS without Exercise Training Program

Cigarette Smoking

Active Comparator group

Description:

Cigarette Smoking + Exercise Training Program Subjects randomized to continued cigarette smoking and participation in an exercise training program.

Treatment:

Other: Cigarette Smoking + Exercise Training Program

Smoking Abstinence

Active Comparator group

Description:

Smoking Abstinence + Exercise Training Program Subjects randomized to smoking abstinence and participation in an exercise training program.